(1/2) randomized evaluation of bromocriptine in myocardial recovery therapy for peripartum cardiomyopathy (rebirth)
Active Cooperative Agreement Awarded Last action
- Award ID
- UH3HL153847
- Recipient
-
University Of Pittsburgh - Of The Commonwealth System Of Higher Education UEI MKAGLD59JRL1
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,940,533
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 87% complete
- Originally
- Place of performance
- Pittsburgh, PA 15213, USA
Award details come from USAspending.gov.
Description
- Abstract
- Peripartum cardiomyopathy (ppcm) is a complication of pregnancy occurring in 1 in 2000 live births, which remains a major cause of maternal morbidity and mortality. Inhibition of prolactin with the dopaminergic agonist bromocriptine appears to improve outcomes in small clinical studies of ppcm in africa and europe; however, no randomized trial has been performed in a diverse multi-racial north american cohort comparing bromocriptine against standard heart failure therapy. This multicenter trial, randomized evaluation of bromocriptine in myocardial recovery therapy for peripartum cardiomyopathy (rebirth), will evaluate whether the addition of bromocriptine to standard therapy improves outcomes for women with ppcm. This trial will randomize 200 women with ppcm to eight weeks of bromocriptine or placebo. Left ventricular ejection fraction will be determined by echocardiography at study entry, and reassessed at 6 and 12 months after randomization to determine whether the addition of bromocriptine improves left ventricular function and overall clinical outcomes. For women presenting with ppcm, echocardiographic assessment of left ventricular dysfunction and remodeling helps predict the probability of recovery. This proposal will evaluate whether global longitudinal strain or left ventricular diastolic volume will predict the therapeutic response to bromocriptine. The therapeutic impact of bromocriptine is theoretically a result of the reduction of prolactin and prolactin fragments collectively known as vasoinhibins. This investigation will investigate whether higher levels of these biomarkers predict greater benefit from bromocriptine. Breastfeeding raises prolactin levels, and the impact of breastfeeding on recovery from ppcm remains controversial. Given that bromocriptine causes cessation of lactation, women with ppcm who want to continue breastfeeding are excluded from the randomized trial. This proposal will follow 50 such women and investigate the levels of these biomarkers and whether the recovery of left ventricular function differs in breastfeeding women. Rebirth will clarify the role of bromocriptine for the treatment of this disorder. This proposal will also evaluate the impact of breastfeeding, and will have a significant impact on the overall management of women with ppcm.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $677,240 | |
| Amendment | $727,524 | |
| Amendment | $122,207 | |
| Amendment | $744,936 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $889,542 | |
| Amendment | $889,542 | |
| Original award | $889,542 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of South Florida | $19,734 | |
| Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University | $22,540 | |
| University Of Florida | $56,358 | |
| The Pennsylvania State University | $16,073 | |
| Hartford Hospital | $16,147 | |
| Yale Univ | $0 | |
| Saint Luke's Hospital Of Kansas City | $0 | |
| The Pennsylvania State University | $57,800 | |
| The Pennsylvania State University | $56,469 | |
| Pennsylvania State University | $141,986 | |
| Virginia Commonwealth University | $10,247 |
Show all 11
Quick answers
Who received award UH3HL153847?
UH3HL153847 was awarded to University Of Pittsburgh - Of The Commonwealth System Of Higher Education by National Heart Lung and Blood Institute (National Institutes of Health) on August 1, 2021.
How much is award UH3HL153847 worth?
$4,940,533 has been obligated on UH3HL153847.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award